Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial
2018 ◽
Vol 21
(1)
◽
pp. 103-111
◽
Keyword(s):
Phase 3
◽
Keyword(s):
2010 ◽
Vol 119
(02)
◽
pp. 63-68
◽
Keyword(s):
2016 ◽
Vol Volume 10
◽
pp. 2599-2609
◽
2010 ◽
Vol 19
(8)
◽
pp. 1017-1025
◽
Keyword(s):
2018 ◽
Vol 21
(1)
◽
pp. 136-145
◽
Keyword(s):
2011 ◽
Vol 65
(9)
◽
pp. 930-938
◽
Keyword(s):
2018 ◽
Vol 20
(9)
◽
pp. 2200-2209
◽
Keyword(s):